Zhengye Biotechnology Holding Ltd (ZYBT) income statement
ZYBTNasdaqPharmaceutical Preparations
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 28, 2026Score 4/30
$1.50−0.02 (-1.32%)
Close on Nov 18, 2026Market cap $71.09MP/E –Yield –
Zhengye Biotechnology Holding Ltd income statement
Ratios
Latest available, balances at Dec 31, 2025
Profitability, FY2025
- Gross margin
- 20.5%
- Operating margin
- -60.6%
- Net margin
- -60.0%
- Return on equity, FY2025
- -26.1%
Financial strength
- Current ratio
- 1.14
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 41.8%
Valuation
- P/E ratio
- –
- Price to sales
- 4.08
- Price to book
- 1.90
- Dividend yield
- –
See a number that looks wrong?